All News

Found 671,254 articles

• Bristol Myers Squibb Receives European Commission Approval for Onureg® (azacitidine tablets) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia

  6/18/2021

  Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has granted full Marketing Authorization for Onureg® (azacitidine tablets) as a maintenance therapy in adult patients with acute myeloid leukemia

• Avanos Medical, Inc. to Present at the 2021 Raymond James Human Health Innovation Conference

  6/18/2021

  Avanos Medical, Inc. announced that Joe Woody, chief executive officer, will present and participate in an analyst-led fireside chat at the Virtual 2021 Raymond James Human Health Innovation Conference Tues., June 22 at approximately 10:40 a.m., ET.

• Aditxt Announces the Appointment of Dr. Lauren Chung to its Board of Directors

  6/18/2021

  Aditx Therapeutics, Inc. announced today that Dr. Lauren Chung will join the Aditxt board of directors as an independent director.

• Predictive Oncology Announces Closing of $21.34 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

  6/18/2021

  Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has completed the closing of its previously announced registered direct offering of 15,520,911 shares of its common stock and warrants

• Praetego Inc Awarded New NIH Funding to Investigate Novel Small Molecule Drug Candidates for Neurodegeneration and Alzheimer's Disease.

  6/18/2021

  Praetego Inc (https://www.praetego.com/), a pharmaceutical company committed to improving health outcomes for patients living with diabetes, is pleased to announce a $0.46M funding award from the National Institutes of Health.

• Scholar Rock to Present Apitegromab TOPAZ Phase 2 Trial Results Highlighting Pharmacokinetic (PK) and Pharmacodynamic (PD) Data at the 2021 European Academy of Neurology Congress

  6/18/2021

  Scholar Rock today announced an oral e-presentation of clinical results from the TOPAZ Phase 2 trial.

• European Commission approves Aubagio® (teriflunomide) as the first oral MS therapy for first-line treatment of children and adolescents living with relapsing-remitting multiple sclerosis

  6/18/2021

  The European Commission (EC) has approved Aubagio® (teriflunomide) for the treatment of pediatric patients 10 to 17 years of age with relapsing-remitting multiple sclerosis (RRMS).

• Nuevocor closes US$24M Series A Financing to Advance Novel Gene Therapies for Cardiomyopathies

  6/18/2021

  Nuevocor, a preclinical-stage biotech company specializing in gene therapy for cardiomyopathies, has announced the completion of an oversubscribed $24 million Series A financing round.

• Exelixis Chief Medical Officer Gisela M. Schwab, M.D., to Take Medical Leave of Absence

  6/18/2021

  Exelixis, Inc. (Nasdaq: EXEL) announced that, effective today, Gisela M. Schwab, M.D., the company’s President, Product Development and Medical Affairs and Chief Medical Officer, has begun a medical leave of absence.

• Co-Diagnostics, Inc Receives CE Marking for Direct Saliva SARS-CoV-2 Test

  6/18/2021

  Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Logix Smart™ SARS-CoV-2 DS (Direct Saliva) has obtained regulatory authorization to be sold as an in vitro diagnostic ("IVD") for the diagnosis of COVID-19 in markets that accept CE markings

• NeoGenomics Completes Inivata Acquisition - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform

  6/18/2021

  NeoGenomics, Inc.announced today that it has completed its acquisition of Inivata Ltd.

• BioXcel Therapeutics to Host Virtual Commercial Day on June 25, 2021Live webcast to be held on June 25th from 12:00 PM ET – 1:30 PM ET

  6/18/2021

  BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, announced that the Company will host a virtual Commercial Day on Friday, June 25, 2021, from 12:00 PM ET – 1:30 PM ET.

• Edesa Biotech Reports Favorable Review of COVID-19 Study

  6/18/2021

  Edesa Biotech, Inc. today reported that an independent Data and Safety Monitoring Board (DSMB) has completed an interim review of the company's COVID-19 drug candidate.

• HUTCHMED Announces NMPA Approval of Surufatinib (Sulanda® in China) for Advanced Pancreatic Neuroendocrine Tumors

  6/18/2021

  HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) today announces that surufatinib has been granted approval for drug registration by the National Medical Products Administration of China (“NMPA”) for the treatment of advanced pancreatic neuroendocrine tumors (“pNETs”).

• Codex DNA Announces Pricing of Initial Public Offering

  6/18/2021

  Codex DNA, Inc., creators of the BioXp™ system, a fully automated benchtop instrument that enables numerous synthetic biology workflows, announced the pricing of its initial public offering of 6,666,665 shares of its common stock at a public offering price of $16.00 per share.

• Jacobio Announces First Two Patients Dosed in SHP2 Combination Study, Triggering US$20 Million Milestone Payment

  6/18/2021

  Jacobio Pharmaceuticals has announced that the first two patients have been dosed in the Phase 1/2a clinical trial of SHP2 inhibitor JAB-3312 in combination with PD-1 antibody Pembrolizumab and MEK inhibitor Binimetinib respectively, thereby triggering the US$20 million milestone payment from AbbVie.

• AnPac Bio’s First Disease Treatment Patent Granted, and Its Cancer Treatment Project Secured Multi-Million Dollar Funds

  6/18/2021

  AnPac Bio-Medical Science Co., Ltd., a biotechnology company with operations in China and the United States focused on early cancer screening and detection as well as cancer treatment, announced that it has been granted its first disease treatment patent by the United States Patent and Trademark Office on June 7, 2021.

• Anivive Announces Positive Study Results for Antifungal Vaccine to Prevent Canine Valley Fever

  6/18/2021

  Anivive, a pet health technology company transforming the therapeutic discovery and development process, announced positive results from a study on its groundbreaking fungal vaccine for Valley Fever in dogs.

• InnoCare Presents Latest Clinical Data of Orelabrutinib at the16th International Conference on Malignant Lymphoma

  6/18/2021

  InnoCare, a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced the company presented the latest clinical data of the Bruton's tyrosine kinase inhibitor orelabrutinib at the 16th International Conference on Malignant Lymphoma.

• deCODE genetics: Predicting the probability of death

  6/18/2021

  Scientists from deCODE genetics have developed a predictor based on protein measurements in blood samples that predicts the time to all-cause death better than traditional risk factors.